Skip to main content

CME Group’s (NASDAQ:CME) Q4 CY2025 Earnings Results: Revenue In Line With Expectations

CME Cover Image

Financial derivatives exchange CME Group (NASDAQ: CME) met Wall Streets revenue expectations in Q4 CY2025, with sales up 8.1% year on year to $1.65 billion. Its non-GAAP profit of $2.77 per share was 1% above analysts’ consensus estimates.

Is now the time to buy CME Group? Find out by accessing our full research report, it’s free.

CME Group (CME) Q4 CY2025 Highlights:

  • Revenue: $1.65 billion vs analyst estimates of $1.64 billion (8.1% year-on-year growth, in line)
  • Pre-tax Profit: $1.58 billion (95.7% margin)
  • Adjusted EPS: $2.77 vs analyst estimates of $2.74 (1% beat)
  • Market Capitalization: $105.7 billion

"Last year, CME Group delivered the best year in our history and our fourth consecutive year of record revenue, adjusted operating income, adjusted net income and adjusted earnings per share," said Terry Duffy, CME Group Chairman and Chief Executive Officer.

Company Overview

Born from the Chicago Mercantile Exchange founded in 1898 as a butter and egg trading venue, CME Group (NASDAQ: CME) operates the world's largest derivatives marketplace where traders can buy and sell futures and options contracts across interest rates, equities, currencies, commodities, and more.

Revenue Growth

A company’s long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Over the last five years, CME Group grew its revenue at a tepid 6% compounded annual growth rate. This was below our standard for the financials sector and is a tough starting point for our analysis.

CME Group Quarterly Revenue

We at StockStory place the most emphasis on long-term growth, but within financials, a half-decade historical view may miss recent interest rate changes, market returns, and industry trends. CME Group’s annualized revenue growth of 8.1% over the last two years is above its five-year trend, suggesting some bright spots. CME Group Year-On-Year Revenue GrowthNote: Quarters not shown were determined to be outliers, impacted by outsized investment gains/losses that are not indicative of the recurring fundamentals of the business.

This quarter, CME Group grew its revenue by 8.1% year on year, and its $1.65 billion of revenue was in line with Wall Street’s estimates.

The 1999 book Gorilla Game predicted Microsoft and Apple would dominate tech before it happened. Its thesis? Identify the platform winners early. Today, enterprise software companies embedding generative AI are becoming the new gorillas. a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.

Key Takeaways from CME Group’s Q4 Results

This was a quarter without many surprises, good or bad. Revenue was in line and EPS beat by 1%. The stock remained flat at $293.04 immediately following the results.

Should you buy the stock or not? We think that the latest quarter is only one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).

Recent Quotes

View More
Symbol Price Change (%)
AMZN  238.34
-0.28 (-0.12%)
AAPL  275.84
+6.36 (2.36%)
AMD  214.48
-27.63 (-11.41%)
BAC  55.44
+0.98 (1.81%)
GOOG  342.40
+1.70 (0.50%)
META  682.62
-9.09 (-1.31%)
MSFT  414.22
+3.01 (0.73%)
NVDA  178.67
-1.67 (-0.93%)
ORCL  148.47
-6.20 (-4.01%)
TSLA  423.26
+1.30 (0.31%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.